The Business Research Company’s report on the Dupixent Market provides insights into the global market size, growth rate, regional distribution, competitive landscape, key segments, emerging trends, and strategic opportunities.
What are the primary drivers fueling the growth of the dupixent market in recent years?
The increasing prevalence of skin allergies is expected to drive the growth of the dupixent market going forward. Skin allergies are immune system reactions to substances that cause irritation or inflammation of the skin, leading to symptoms such as redness, itching, rashes, or swelling. The rising skin allergies is due to factors such as increased environmental pollution, changes in diet, higher levels of stress, and greater exposure to allergens like chemicals, fragrances, and harsh skincare products. Dupixent helps skin allergy by targeting and inhibiting specific immune pathways, such as interleukin-4 and interleukin-13 signaling, which are key drivers of inflammation, thereby reducing symptoms like itching, redness, and swelling while improving overall skin health and quality of life. For instance, in October 2023, according to the European Academy of Dermatology and Venereology (EADV), a Switzerland-based non-profit association, a survey of 44,689 adults across 27 European countries, including the EU, UK, Norway, and Switzerland, found that 43% of EU citizens experienced at least one skin condition in the past year. The most common conditions reported were fungal skin infections, atopic dermatitis (eczema), alopecia, and acne. Therefore, the increasing prevalence of skin allergies is driving the growth of the dupixent market.
Rising Healthcare Expenditure Boosts Growth In The Dupixent Market
The rising healthcare expenditure is expected to drive the growth of the dupixent market going forward. Healthcare expenditure is the total amount of financial resources spent on the provision and consumption of healthcare services within a specific region or country. The rising healthcare expenditure is due to various factors such as an aging population, rising chronic diseases, advanced medical technology, inflation, expanded access to care, and higher drug and administrative costs. Healthcare expenditure supports dupixent by driving investments in innovative biologic treatments, enabling broader access and adoption of advanced therapies for chronic conditions such as asthma and atopic dermatitis, which align with the growing focus on improving patient outcomes and managing long-term healthcare costs effectively. For instance, in May 2024, according to the Office for National Statistics, a UK-based government agency, the UK’s healthcare expenditure reached approximately $306 billion (£292 billion) in 2023. This marked a 5.6% increase in nominal terms from 2022, a significant rise compared to the 0.9% growth observed in the previous year. Therefore, the rising healthcare expenditure is driving the growth of the dupixent market.
Access Your Free Sample of the Global Dupixent Market Report – Get Insights Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=19897&type=smp
What is the projected market size of the dupixent industry, and how is it expected to grow?
The dupixent market size has XX (HCAGR) in recent years. It will grow from $XX million in 2024 to $XX million in 2025 at a compound annual growth rate (CAGR) of XX%. The growth in the historic period can be attributed to increased demand for new treatment options, rise in awareness and patient advocacy, increased focus on specialty pharmacy networks, increased rate of recurrence of disease, increased public awareness of atopic dermatitis.
The dupixent market size is expected to see XX (FCAGR) in the next few years. It will grow to $XX million in 2029 at a compound annual growth rate (CAGR) of XX%. The growth in the forecast period can be attributed to increasing prevalence of chronic inflammatory diseases, growing patient population and aging demographics, growing awareness and improved diagnosis, growing focus on personalized medicine, increasing prevalence of skin allergies. Major trends in the forecast period include advancements in biologics and biotechnology, real-world evidence (RWE) and data analytics, artificial intelligence (AI) and machine learning (ML) in drug discovery, therapeutic technologies.
Gain Exclusive Market Insights—Customize Your Research Report Today For Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=19897&type=smp
Who are the key players driving competition in the dupixent market?
Major companies operating in the dupixent market include Sanofi SA, Regeneron Pharmaceuticals Inc.
What key trends are expected to drive the daratumumab or darzalex market during the forecast period?
The key trend in the dupixent market is focusing on developing innovative products, such as biologic medicines, to offer targeted treatments that can effectively address complex diseases. Biologic medicines are therapeutic products derived from living organisms or their cells, used to treat various diseases by targeting specific components of the immune system or other biological pathways. For instance, in June 2022, Sanofi SA, a France-based pharmaceutical company, together with Regeneron Pharmaceuticals Inc., a US-based biotechnology company, announced the U.S. Food and Drug Administration (FDA) approval for Dupixent (dupilumab) for children with moderate-to-severe atopic dermatitis between the ages of 6 months and 5 years, when topical prescription medications are either insufficient to control the condition or not recommended. Dupixent is the first and only biologic medicine approved for treating moderate-to-severe atopic dermatitis in patients ranging from infancy to adulthood. In a Phase 3 trial, children treated with Dupixent alongside topical corticosteroids (TCS) showed significantly clearer skin and reduced itching at week 16 compared to those using TCS alone. Additionally, long-term safety data from a 52-week open-label extension trial in this age group support the well-established safety profile of Dupixent, consistent with its use in other approved age groups.
Which key geographies are driving the growth of the dupixent market?
North America was the largest region in the dupixent market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the dupixent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Order Your Report Now For Swift Delivery
https://www.thebusinessresearchcompany.com/report/dupixent-global-market-report
What are the key segments driving growth in the dupixent market?
The dupixentmarket covered in this report is segmented –
1) By Indication: Atopic Dermatitis; Asthma; Chronic Rhinosinusitis With Nasal Polyps; Eosinophilic Esophagitis; Prurigo Nodularis
2) By Distribution Channel: Hospital Pharmacies; Specialty Pharmacies; Outpatient Treatment Centers
Purchase The Exclusive Report Now To Unlock Valuable Market Insights:
https://www.thebusinessresearchcompany.com/customise?id=19897&type=smp
How is the dupixent market defined?
Dupixent is a prescription medication used to treat a variety of chronic inflammatory conditions, primarily in individuals with moderate to severe forms of certain diseases. It is a monoclonal antibody that works by inhibiting specific immune system proteins, particularly interleukin-4 (IL-4) and interleukin-13 (IL-13), which play a key role in inflammation and allergic responses. Dupixent is typically administered as an injection, either subcutaneously or through a pre-filled pen.
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
